Sep 20, 2010
San Francisco
This conference brings you up to speed on how to best address complex issues including data ownership and control, contractual rights, open source license compliaince and much more

Sep 27 - 28, 2010
Philadelphia
Effectively responding to the government and mitigating liability when under investigation is an art that must be mastered in these times of massive government enforcement and action against the pharmaceutical and device industries.

Sep 27 - 28, 2010
Boston
Increase your FDA regulatory knowledge to become a better life sciences products litigator or patent attorney The approval process…pre-approval concerns…product labeling…clinical trials…adverse events reports…patent concerns…exclusivity. FDA law and regulations govern these critical aspects in the commercialization process for drugs, biologics, and devices. Recent court cases and high-profile litigation concerning FDA-regulated products have made it clear that it is essential for attorneys who do not have regulatory practices – but who deal with FDA-regulated products – to understand the rules and regulations that impact the life sciences arena.

Oct 06 - 07, 2010
New York City
Now is the time to come to the one and only event that has consistently allowed brand name and generic drug makers to benchmark their companies’ current Hatch-Waxman strategies and tactics against competitors in both camps.

Oct 18 - 19, 2010
Philadelphia
The essential cross-industry forum for corporate and outside counsel who are truly motivated to create value and reduce legal costs through innovative fee arrangements, enhanced relationships, and streamlined operations

Oct 21 - 22, 2010
Philadelphia
Alternative fee arrangements, convergence trends, qualitative approaches to selecting, retaining & managing outside counsel, and other strategies for minimizing in-house legal department costs & fi nancial risk without compromising work product or quality

Oct 26 - 27, 2010
New York City
ACI’s Physician Payments Disclosure & Aggregate Spend conference will explore the next level of state reporting and aggregate spend issues by honing in on best practices employed by drug and device manufacturers as well as clarification of ambiguous state

Oct 27 - 28, 2010
Chicago
A unique opportunity to get highly-specialized, up-to-the minute information straight from the source, in a setting where you can network with your peers while also getting answers to your specific questions and concerns.

Nov 15 - 17, 2010
NEW YORK
Learn to navigate the European regulatory maze that plays such an essential part in the successful commercialization of pharmaceutical and biological products.

Nov 17 - 18, 2010
New York
ACI’s Rx Drug Pricing Boot Camp has been designed to provide drug manufacturers, PBMs, plans, and pharmacies with the critical information they need to effectively and efficiently manage government pricing.

Nov 30 - Dec 01, 2010
Boston
ACI aims to provide a forum to analyze the latest developments that are keeping biotech practitioners up at night and arm them with the tools to proceed with certainty through one of the trickiest practice areas to navigate.

Dec 07 - 09, 2010
New York
At the 15th Annual Drug and Medical Device Litigation, our diverse in-house faculty speakers will provide insights into the business implications of mass tort litigation as well as practical litigation approaches every defense counsel can employ.

Dec 08 - 09, 2010
San Francisco
ACI’s Paragraph IV Disputes --- the first and original conference of its kind --- is the most trusted source for the ‘ins and outs’ of Paragraph IV litigation.

Jan 26 - 27, 2011
New York
Learn the nuts and bolts of patent lifecycle longevity. Hear from those on the forefront of Wyeth and Japan Tobacco

May 03 - 04, 2011
New York City
ACI’s Paragraph IV Disputes conference has been designed to give counsel for both brand name and generic drug companies the critical up-to-the minute information that they need to plan their Hatch-Waxman litigation strategies

Jun 22 - 23, 2011
New York
Follow on Biologics will provide you with the most in-depth analysis of the legal, regulatory, policy and business issues surrounding follow-on biologics.